These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34337560)

  • 1. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
    Raman S; Buongervino SN; Lane MV; Zhelev DV; Zhu Z; Cui H; Martinez B; Martinez D; Wang Y; Upton K; Patel K; Rathi KS; Navia CT; Harmon DB; Li Y; Pawel B; Dimitrov DS; Maris JM; Julien JP; Bosse KR
    Cell Rep Med; 2021 Jul; 2(7):100344. PubMed ID: 34337560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
    Bosse KR; Raman P; Zhu Z; Lane M; Martinez D; Heitzeneder S; Rathi KS; Kendsersky NM; Randall M; Donovan L; Morrissy S; Sussman RT; Zhelev DV; Feng Y; Wang Y; Hwang J; Lopez G; Harenza JL; Wei JS; Pawel B; Bhatti T; Santi M; Ganguly A; Khan J; Marra MA; Taylor MD; Dimitrov DS; Mackall CL; Maris JM
    Cancer Cell; 2017 Sep; 32(3):295-309.e12. PubMed ID: 28898695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
    Pascual-Pasto G; McIntyre B; Shraim R; Buongervino SN; Erbe AK; Zhelev DV; Sadirova S; Giudice AM; Martinez D; Garcia-Gerique L; Dimitrov DS; Sondel PM; Bosse KR
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
    Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
    Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
    Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
    Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
    Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
    Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
    Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
    Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating
    Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
    Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
    Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.
    Li N; Ho M
    Methods Mol Biol; 2022; 2446():451-468. PubMed ID: 35157288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children.
    Li M; Zhang X; Liu J; Zhou C; Miao L; He J; Wu H; Zhang R
    J Clin Lab Anal; 2023 Mar; 37(5):e24866. PubMed ID: 36920409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
    Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
    Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.
    Sano R; Krytska K; Larmour CE; Raman P; Martinez D; Ligon GF; Lillquist JS; Cucchi U; Orsini P; Rizzi S; Pawel BR; Alvarado D; Mossé YP
    Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
    Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
    Front Immunol; 2022; 13():857308. PubMed ID: 35345673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma.
    Yokota K; Serada S; Tsujii S; Toya K; Takahashi T; Matsunaga T; Fujimoto M; Uemura S; Namikawa T; Murakami I; Kobayashi S; Eguchi H; Doki Y; Hanazaki K; Naka T
    Mol Cancer Ther; 2021 Sep; 20(9):1713-1722. PubMed ID: 34224365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
    Feng Y; Wang Y; Zhu Z; Li W; Sussman RT; Randall M; Bosse KR; Maris JM; Dimitrov DS
    MAbs; 2016; 8(4):799-810. PubMed ID: 26910291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.